Seroreactivity with the Plasmodium Falciparum Blood Stage Antigen Pf332 in Adults and Children from Malaria-endemic Regions

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1993 Oct 1

PMID 8403520

Citations 2

Authors

J Iqbal

P Perlmann

B M Greenwood

K Berzins

Affiliations

Soon will be listed here.

Abstract

It has earlier been reported that the human monoclonal antibody (MoAb 33G2) and polyclonal antibodies reactive with Pf332 may interfere in vitro with the erythrocytic cycle of Plasmodium falciparum at two potential target sites for protective antibodies, indicating that the antigen may constitute an important target for immune responses during malaria infections. MoAb 33G2 shows its highest reactivity with repeated sequences in the antigen Pf332 and also cross-reacts with determinants in Pf155/RESA. This study was conducted in order to assess the prevalence of seroreactivity against Pf332 in individuals residing in areas of different malaria endemicity, and in children with different degrees of disease severity. We now report that individuals resident in malaria-endemic regions show a high prevalence of seroreactivity to antigen Pf332 repeat sequences. The mean antibody concentrations were significantly higher in donors from Liberia, Madagascar and Gambia compared with Thai and Colombian donors, probably reflecting the higher degree of exposure in the African regions. Although the levels of such antibodies in individual sera correlated well with the levels of antibodies to one Pf155/RESA repeat peptide, only a minor part of the peptide-reactive antibodies were cross-reactive between the two antigens. In Gambian children, the mean concentrations of antibodies reactive with Pf332 or Pf155/RESA peptides were significantly higher in children with severe than with mild malaria. Further longitudinal studies are needed to evaluate the capacity of Pf332 to induce potentially protective or harmful antibody responses.

Citing Articles

Characterization of the Duffy-Binding-Like Domain of Plasmodium falciparum Blood-Stage Antigen 332.

Nilsson S, Moll K, Angeletti D, Albrecht L, Kursula I, Jiang N Malar Res Treat. 2012; 2011:671439.

PMID: 22312570 PMC: 3269649. DOI: 10.4061/2011/671439.

Antibody responses to a C-terminal fragment of the Plasmodium falciparum blood-stage antigen Pf332 in Senegalese individuals naturally primed to the parasite.

Israelsson E, Balogun H, Vasconcelos N, Beser J, Roussilhon C, Rogier C Clin Exp Immunol. 2008; 152(1):64-71.

PMID: 18279441 PMC: 2384058. DOI: 10.1111/j.1365-2249.2008.03607.x.

References

Anders R . Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria. Parasite Immunol. 1986; 8(6):529-39. DOI: 10.1111/j.1365-3024.1986.tb00867.x. View

Ahlborg N, Berzins K, Perlmann P . Definition of the epitope recognized by the Plasmodium falciparum-reactive human monoclonal antibody 33G2. Mol Biochem Parasitol. 1991; 46(1):89-95. DOI: 10.1016/0166-6851(91)90202-h. View

Molyneux M, Taylor T, Wirima J, Borgstein A . Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med. 1989; 71(265):441-59. View

Perrin L, Simitsek P, Srivastava I . Development of malaria vaccines. Trop Geogr Med. 1988; 40(3):S6-21. View

Mattei D, Scherf A . The Pf332 gene of Plasmodium falciparum codes for a giant protein that is translocated from the parasite to the membrane of infected erythrocytes. Gene. 1992; 110(1):71-9. DOI: 10.1016/0378-1119(92)90446-v. View

Udomsangpetch R, Aikawa M, Berzins K, Wahlgren M, Perlmann P . Cytoadherence of knobless Plasmodium falciparum-infected erythrocytes and its inhibition by a human monoclonal antibody. Nature. 1989; 338(6218):763-5. DOI: 10.1038/338763a0. View

Erunkulu O, Hill A, Kwiatkowski D, TODD J, Iqbal J, Berzins K . Severe malaria in Gambian children is not due to lack of previous exposure to malaria. Clin Exp Immunol. 1992; 89(2):296-300. PMC: 1554452. DOI: 10.1111/j.1365-2249.1992.tb06948.x. View

Bjorkman A, Hedman P, Brohult J, Willcox M, Diamant I, Pehrsson P . Different malaria control activities in an area of Liberia--effects on malariometric parameters. Ann Trop Med Parasitol. 1985; 79(3):239-46. DOI: 10.1080/00034983.1985.11811914. View

Tharavanij S, Warrell M, Tantivanich S, Tapchaisri P, Chongsa-nguan M, Prasertsiriroj V . Factors contributing to the development of cerebral malaria. I. Humoral immune responses. Am J Trop Med Hyg. 1984; 33(1):1-11. DOI: 10.4269/ajtmh.1984.33.1. View

10.

Wahlin B, Sjolander A, Ahlborg N, Udomsangpetch R, Scherf A, Mattei D . Involvement of Pf155/RESA and cross-reactive antigens in Plasmodium falciparum merozoite invasion in vitro. Infect Immun. 1992; 60(2):443-9. PMC: 257647. DOI: 10.1128/iai.60.2.443-449.1992. View

11.

Greenwood B, Armstrong J . Comparison of two simple methods for determining malaria parasite density. Trans R Soc Trop Med Hyg. 1991; 85(2):186-8. DOI: 10.1016/0035-9203(91)90015-q. View

12.

Perlmann H, Perlmann P, Berzins K, Wahlin B, Troye-Blomberg M, Hagstedt M . Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components. Immunol Rev. 1989; 112:115-32. DOI: 10.1111/j.1600-065x.1989.tb00555.x. View

13.

Chizzolini C, Dupont A, Akue J, Kaufmann M, Verdini A, Pessi A . Natural antibodies against three distinct and defined antigens of Plasmodium falciparum in residents of a mesoendemic area in Gabon. Am J Trop Med Hyg. 1988; 39(2):150-6. DOI: 10.4269/ajtmh.1988.39.150. View

14.

Perlmann H, Berzins K, Wahlgren M, Carlsson J, Bjorkman A, Patarroyo M . Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med. 1984; 159(6):1686-704. PMC: 2187329. DOI: 10.1084/jem.159.6.1686. View

15.

Mattei D, Hinterberg K, Scherf A . Pfl I-I and Pf332: two giant proteins synthesized in erythrocytes infected with Plasmodium falciparum. Parasitol Today. 1992; 8(12):426-8. DOI: 10.1016/0169-4758(92)90197-a. View

16.

Udomsangpetch R, Carlsson J, Wahlin B, Holmquist G, Ozaki L, Scherf A . Reactivity of the human monoclonal antibody 33G2 with repeated sequences of three distinct Plasmodium falciparum antigens. J Immunol. 1989; 142(10):3620-6. View

17.

Udomsangpetch R, Lundgren K, Berzins K, Wahlin B, Perlmann H, Troye-Blomberg M . Human monoclonal antibodies to Pf 155, a major antigen of malaria parasite Plasmodium falciparum. Science. 1986; 231(4733):57-9. DOI: 10.1126/science.3510452. View

18.

FRIBOURG-BLANC A, Druilhe P, Brasseur P, Ballet J, Tharavanij S . Immunological evaluation of cell-mediated and humoral immunity in Thai patients with cerebral and non cerebral Plasmodium falciparum malaria: II. Evolution of serum levels of immunoglobulins, antimalarial antibodies, complement fractions and alpha.... Southeast Asian J Trop Med Public Health. 1985; 16(2):307-13. View

19.

Lepers J, Deloron P, Ramanamirija J, Coulanges P . Newly transmitted Plasmodium falciparum malaria in the central highland plateaux of Madagascar: assessment of clinical impact in a rural community. Bull World Health Organ. 1990; 68(2):217-22. PMC: 2393115. View

20.

Riley E, Allen S, Troye-Blomberg M, Bennett S, Perlmann H, Andersson G . Association between immune recognition of the malaria vaccine candidate antigen Pf155/RESA and resistance to clinical disease: a prospective study in a malaria-endemic region of west Africa. Trans R Soc Trop Med Hyg. 1991; 85(4):436-43. DOI: 10.1016/0035-9203(91)90207-f. View